BranchLab: Edgar Simard Joins Scientific Advisory Board To Guide Healthcare AI Development

BranchLab has appointed epidemiology and real-world evidence specialist Edgar Simard to its Scientific Advisory Board as the company strengthens the scientific framework supporting its artificial intelligence platform for healthcare commercialization.

Simard brings more than 25 years of experience in epidemiology, population health, and real-world data strategy. He is executive director and head of global epidemiology and real-world data strategy at Revolution Medicines and will serve on BranchLab’s advisory board in a personal capacity.

His previous experience includes establishing and leading epidemiology and real-world evidence functions at Verily, Medtronic, GSK, and Aetion. He also held research positions at the National Cancer Institute, Centers for Disease Control and Prevention, American Cancer Society, and Emory University.

Simard’s work focuses on using scientific evidence to understand patient populations, treatment patterns, and unmet medical needs throughout the pharmaceutical product lifecycle. That experience is relevant to BranchLab’s effort to apply AI to commercial decision-making while maintaining transparent methods and well-defined patient populations.

The company’s interdisciplinary Scientific Advisory Board brings together specialists in artificial intelligence, healthcare, human-AI collaboration, epidemiology, and population science. The group advises BranchLab on the development of Pathwai, its semantic activation platform.

Pathwai is designed to help healthcare organizations and their agencies connect patients, caregivers, and providers with therapies and other resources. BranchLab developed the system to improve commercialization without depending on individual-level health information, reflecting the industry’s changing privacy requirements.

Simard has published more than 50 peer-reviewed studies covering cancer epidemiology, population health, and the global burden of disease. His research has received more than 60,000 citations. He holds a doctorate in epidemiology from Rutgers University and a master’s degree in public health from Emory University.

KEY QUOTES:

“Commercial decisions in healthcare increasingly rely on complex data and AI, but they rarely face the same evidentiary standards we expect in clinical research and epidemiology. I’m interested in helping close that gap in a fit-for-purpose way: Making sure the populations these models describe are well defined and the methods are transparent and rigorous. BranchLab is well positioned to move the industry forward because of its multidisciplinary approach and grounding in scientific best practice, and I look forward to contributing to that work.”

Edgar Simard, Member of the BranchLab Scientific Advisory Board

“Dr. Simard brings a perspective that spans the pharmaceutical lifecycle, from scientific discovery to real-world impact. He understands how real-world data can create robust scientific evidence and inform meaningful decisions within healthcare organizations. That experience adds valuable context to the development of Pathwai and how we help healthcare organizations understand patient populations and make better commercial decisions.”

Kat Drake, PhD, Vice President of Data Science and AI at BranchLab